PT-141 (Bremelanotide)
여성 성흥분 장애 치료제로 FDA 승인됨
개요
PT-141 (Bremelanotide)은 멜라노코르틴 수용체 작용제로, 폐경 전 여성의 저활성 성욕장애(HSDD) 치료를 위해 FDA 승인을 받았습니다.
Key Information
Mechanism
뇌의 멜라노코르틴 수용체, 특히 MC4R을 활성화하여 혈관계와 독립적으로 성욕을 증가시킵니다.
Benefits
- 성욕 증가
- HSDD에 대한 FDA 승인
- 뇌 매개 작용 (혈관성 아님)
- 필요 시 사용
Side Effects
- 메스꺼움 (40%)
- 홍조
- 두통
- 피부 어두워짐
Contraindications
- Cardiovascular disease
- Pregnancy
Evidence Summary
저활성 성욕장애에 대한 3상 임상시험을 바탕으로 FDA 승인을 받았습니다.
Research
3상 임상시험에서 성적 욕구 및 이와 관련된 고통의 유의미한 개선이 입증됨에 따라 Vyleesi라는 상품명으로 FDA 승인을 받았습니다.
View ResearchSafety
FDA 승인. 부작용: 메스꺼움, 홍조, 두통.
Frequently Asked Questions About PT-141 (Bremelanotide)
What is PT-141 (Bremelanotide)?
PT-141 (Bremelanotide) is a research peptide also known as Bremelanotide; Vyleesi. 여성 성흥분 장애 치료제로 FDA 승인됨 It is studied for its potential therapeutic applications and is available from various research chemical vendors.
How does PT-141 (Bremelanotide) work?
뇌의 멜라노코르틴 수용체, 특히 MC4R을 활성화하여 혈관계와 독립적으로 성욕을 증가시킵니다.
What is the recommended dosage for PT-141 (Bremelanotide)?
The commonly studied dosage range for PT-141 (Bremelanotide) is 1.75 mg as needed. Dosage protocols vary based on research objectives. Always consult published studies and start with conservative amounts. PT-141 (Bremelanotide) should only be used in controlled research settings.
Where can I buy PT-141 (Bremelanotide)?
PepsReview indexes PT-141 (Bremelanotide) pricing from multiple vendors. Check the Vendors tab above for a price comparison table showing cost per milligram, purity, COA status, and stock availability. Vendor reviews from real users are available on each vendor's profile page.
Is PT-141 (Bremelanotide) legal?
US regulatory status: FDA-approved (Vyleesi). The legal status of PT-141 (Bremelanotide) varies by jurisdiction. In most countries, it is sold as a research chemical, not for human consumption. Always verify the legal status in your country before purchasing.
What are the side effects of PT-141 (Bremelanotide)?
Reported side effects include: 메스꺼움 (40%), 홍조, 두통, 피부 어두워짐. Always review safety data and published studies before use.
Key Research Papers on PT-141 (Bremelanotide)
The following peer-reviewed studies and clinical trials are indexed in our research library for PT-141 (Bremelanotide). Each paper links to a detailed summary with key findings, study design, and publication metadata.
- PT-141 Palatin — Curr Opin Investig Drugs, 2004 (440 citations)
- An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist — J Sex Med, 2006 (400 citations)
- Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder — Ann Pharmacother, 2020 (120 citations)
- Hypoactive Sexual Desire Disorder in Women: Physiology, Assessment, Diagnosis, and Treatment — J Midwifery Womens Health, 2021 (100 citations)
- Bremelanotide for Treatment of Female Hypoactive Sexual Desire — Neurol Int, 2022 (80 citations)
Write a Review
Login to write a review
You need an account to share your experience with PT-141 (Bremelanotide).
가입Rating Breakdown
Based on 2 리뷰.
리뷰
PT-141 (bremelanotide) restored my libido completely. The fact it's FDA-approved for HSDD is a major plus. Brain-mediated mechanism is different from vascular drugs - works on desire not just blood flow. On-demand use is convenient.
PT-141 takes about 2 hours to kick in. The desire increase is real - not just physical. Nausea is the main side effect. FDA approval makes me feel safe. Better than PDE5 inhibitors for psychological ED.